BNT113 plus pembrolizumab failed to significantly extend progression-free survival in a 285-patient HPV16-positive head and neck cancer trial.
Commentary|Articles|August 14, 2023
Unpacking Regenerative Medicines and Start-Up Funding with Luis Alvarez
Author(s)Grant Playter
Luis Alvarez, PhD, founder of Theradaptive, candidly discusses how his regenerative therapy start-up evolved and secured start-up funding.
Advertisement
Luis Alvarez, PhD, is the founder of
Advertisement
Related to this article
Viking Therapeutics has started two Phase 3 trials of once-daily oral VK2735, a dual GLP-1/GIP receptor agonist, in adults with obesity, with and without type 2 diabetes.
Gilead will develop up to three PRO-XTEN T-cell engagers discovered by Vir Biotechnology for solid tumors in a deal worth up to $1.74 billion.
The FDA has accepted Pierre Fabre Pharmaceuticals’ resubmitted BLA for tabelecleucel, an allogeneic T-cell immunotherapy for EBV+ post-transplant lymphoproliferative disease. The FDA’s target action date is March 31, 2027.
Johnson & Johnson's guselkumab achieved up to 29% fistula remission in hard-to-treat Crohn disease subgroups, including prior biologic failures.
Rona's ALK7 RNAi candidate, licensed to Roche for up to $1.06 billion in milestones, aims to cut visceral fat while sparing lean mass.
Odyssey's 146-patient phase 2a trial will pair OD-001 with vedolizumab, targeting both innate and adaptive immune drivers of ulcerative colitis.
MT027, T-MAXIMUM's B7-H3 CAR-T therapy, earns a second FDA-cleared phase 2 trial, now testing lung and breast cancer brain metastases.
Advertisement
Advertisement
Trending on BioPharm International
1
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
2
RYZ101 Meets Phase 3 Primary Endpoint in Neuroendocrine Tumors After Lutetium-177 Therapy
3
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
4
FDA’s ARC Program Highlights Opportunities and Limits of Bayesian Methods in Rare Disease Trials
5